| | | | % Added dietary CLA | | | | Reference | No. per treatment | Study days | CLA Mix | trans-10 cis-12 | Treatment | Treatment dose, %1 | Observations |
| [136] | 3 to 6 | 28 | 2.0 | 0.95 | Leptin | 5 μg/d | ↓ Hepatic steatosis, ↑ insulin sensitivity, | [40] | 5 to 14 | 30 | 1.0 | 0.72 | Leptin | 5 μg/d | ↑ insulin sensitivity, ameliorated hepatic steatosis | [49] | 5 | 28 | 1.5 | 0.60 | Rosiglitazone | 10 mg/kg BW | ↑ Insulin sensitivity, prevented depletion of epididymal adipose tissue | [35] | 10 | 42 | 2.0 | 1.00 | Rosiglitazone | 10 mg/kg BW | ↓ Hepatic TG content, ↓ hepatic lipogenesis,↑ serum leptin and adiponectin, prevents lipodystrophy | [140] | 7 | 28 | 3.0 | 0.98 | Arachidonic acid | 1, 2 | ↓ Induction of hepatic steatosis, ↑ liver PGE2, ↑ epididymal adipose | [44] | 7 | 28 | — | 1.20 | γ-Linolenic acid | 5 | ↓ Hepatic steatosis, ↑ PGE2 | [38] | 10 | 56 | — | 0.50 | Flax seed oil (α- Linolenic acid) | 0.39 | ↓ Steatosis, ↑ n-3 and n-6 PUFA in liver | [27] | 7 to 8 | 22 | 1.0 | 0.50 | Fish oil | 1.5, 3, 6 | ↑ Leptin and Adiponectin, ↓ Insulin, ↓ TG in liver, ↑ fat pad | [141] | 10 | 105 | 1.0 | 0.50 | Pine oil | 7.5 | Serum insulin levels stabilized over 3 weeks | [135] | 5 to 6 | 100 | 1.0 | 0.35 | 34% dietary fat | | Normal plasma insulin levels, ↑ liver weight | [45] | 6 | 28 | 2.0 | 0.74 | DHA | 0.5 | ↓ Fatty liver, ↓ FA synthesis, plasma leptin, and adiponectin unaffected | [142] | 10 | 56 | — | 0.50 | DHA, EPA | 0.5, 0.5 | Prevented hepatic steatosis, partially restored plasma leptin, only DHA restored plasma adiponectin |
|
|